Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24180069 | 0.85 | AR (0.47) | L3MBTL1MAPTNPSR1CACNA1GCACNA1H | |
| SCHEMBL8566509 | 0.84 | GABRA1 (0.39) | L3MBTL1MAPTNPSR1CACNA1GCACNA1H | |
| SCHEMBL18997033 | 0.82 | L3MBTL1 (0.56) | L3MBTL1MAPTNPSR1HPGDATM | |
| SCHEMBL22389474 | 0.81 | RIPK1 (0.57) | L3MBTL1MAPTNPSR1CACNA1GCACNA1H | |
| SCHEMBL28288419 | 0.81 | MAPT (0.52) | L3MBTL1MAPTNPSR1HPGDSLC6A2 | |
| SCHEMBL7363346 | 0.81 | MAPT (0.46) | L3MBTL1MAPTNPSR1HPGDCACNA1G | |
| SCHEMBL5416008 | 0.81 | SLC6A2 (0.45) | L3MBTL1MAPTNPSR1CACNA1GCACNA1H | |
| SCHEMBL14486495 | 0.81 | SLC6A2 (0.45) | L3MBTL1MAPTNPSR1CACNA1GCACNA1H | |
| SCHEMBL22957694 | 0.80 | MCL1 (0.58) | CACNA1GCACNA1HCACNA1ISLC6A2SLC6A4 | |
| SCHEMBL513917 | 0.80 | SLC6A2 (0.42) | L3MBTL1MAPTNPSR1CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| US-7888345-B2 | Benzaepinones as sodium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888345-B2 | Benzaepinones as sodium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | L3MBTL1 101/4885MAPT 3844/4885NPSR1 1615/4885 |
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | TRPV1, TRPA1, KCNN1 | L3MBTL1 4345/4885MAPT 1034/4885NPSR1 309/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | L3MBTL1 142/4885MAPT 3532/4885NPSR1 3037/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | L3MBTL1 1436/4885MAPT 1202/4885NPSR1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.